



Renal Cell Carcinoma (66.4.C2): sc-65231

BACKGROUND

Renal Cell Carcinoma, also referred to as a gurnistical tumor, is the most common form of kidney cancer in adults. Renal Cell Carcinoma tumor cells tend to form cords, papillae, tubules or nests, and are atypical, polygonal and large. These cells accumulate glycogen and lipids, causing their cytoplasm to appear clear. Renal Cell Carcinoma causes an increased secretion of vasoactive substances such as Renin, which may cause arterial hypertension; Renin leads to the release of erythropoietin, which may lead to polycythemia. Renal Cell Carcinoma arises from the renal tubule and is resistant to radiation therapy and chemotherapy, although some cases respond to immunotherapy. Medications such as α -interferon and interleukin-2 are somewhat successful in reducing the growth of some Renal Cell Carcinomas, including some that have metastasized. The glycoprotein gp200 is expressed by 93% of primary and 84% of metastatic renal cell carcinomas and localizes along the brush border of the proximal tubule and luminal surface of Bowman's capsule. It is commonly expressed on the plasma membrane. Apart from Renal Cell Carcinoma, this antigenic expression is noted in relatively few carcinomas, including mammary carcinomas, teratocarcinomas and parathyroid adenomas.

REFERENCES

1. Nakada, T., Koike, H. and Katayama, T. 1989. Changes of vasoactive substances following embolization for Renal Cell Carcinoma. *Int. Urol. Nephrol.* 20: 569-576.
2. Steffens, J., Bock, R., Braedel, H.U., Isenberg, E., Bührle, C.P. and Ziegler, M. 1990. Renin-producing Renal Cell Carcinoma. *Eur. Urol.* 18: 56-60.
3. Yang, A.H., Chiang, H. and Liu, H.C. 1991. Invasiveness of Renal Cell Carcinoma—an *in vitro* model. *Exp. Mol. Pathol.* 53: 191-202.
4. Oto, A., Herts, B.R., Remer, E.M. and Novick, A.C. 1998. Inferior vena cava tumor thrombus in Renal Cell Carcinoma: staging by MR imaging and impact on surgical treatment. *AJR Am. J. Roentgenol.* 171: 1619-1624.
5. Wong, M., Goldstein, D., Woo, H., Testa, G. and Gurney, H. 2002. α -interferon 2a and 1 3-*cis*-retinoic acid for the treatment of metastatic Renal Cell Carcinoma. *Intern. Med. J.* 32: 158-162.
6. Wu, S.L., Fishman, I.J. and Shannon, R.L. 2002. Chromophobe Renal Cell Carcinoma with extensive calcification and ossification. *Ann. Diagn. Pathol.* 6: 244-247.
7. Flanigan, R.C., Mickisch, G., Sylvester, R., Tangen, C., Van Poppel, H. and Crawford, E.D. 2004. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. *J. Urol.* 171: 1071-1076.
8. Sawada, N., Fukasawa, M., Araki, I., Kira, S., Manabu, K. and Takeda, M. 2005. Multifocal metastases of recurrent Renal Cell Carcinoma successfully treated with a combination of low dose interleukin-2, α -interferon and radiotherapy. *Int. J. Urol.* 12: 994-995.
9. Israel, G.M. and Bosniak, M.A. 2005. How I do it: evaluating renal masses. *Radiology* 236: 441-450.

SOURCE

Renal Cell Carcinoma (66.4.C2) is a mouse monoclonal antibody raised against renal cortical tissue of human origin.

PRODUCT

Each vial contains 100 μ g IgG_{2b} in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

Renal Cell Carcinoma (66.4.C2) is recommended for detection of Renal Cell Carcinoma of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500).

SELECT PRODUCT CITATIONS

1. Fadare, O., Desouki, M.M., Gwin, K., Hanley, K.Z., Jarboe, E.A., Liang, S.X., Quick, C.M., Rawish, K.R., Roma, A.A., Zheng, W., Hecht, J.L., Parkash, V. and Osunkoya, A.O. 2018. Clear cell Renal Cell Carcinoma metastatic to the gynecologic tract: a clinicopathologic analysis of 17 cases. *Int. J. Gynecol. Pathol.* 37: 525-535.

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.